160,000 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Purchased by Stonepine Capital Management LLC

Stonepine Capital Management LLC purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 160,000 shares of the company's stock, valued at approximately $570,000. Stonepine Capital Management LLC owned 0.18% of Aquestive Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AQST. Vanguard Group Inc. grew its stake in shares of Aquestive Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock valued at $15,474,000 after buying an additional 82,958 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in Aquestive Therapeutics by 6.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company's stock worth $3,505,000 after acquiring an additional 61,200 shares during the period. Bank of America Corp DE boosted its holdings in Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock worth $2,457,000 after acquiring an additional 621,614 shares during the period. Northern Trust Corp grew its position in Aquestive Therapeutics by 3.1% in the fourth quarter. Northern Trust Corp now owns 599,812 shares of the company's stock valued at $2,135,000 after acquiring an additional 18,199 shares in the last quarter. Finally, Bracebridge Capital LLC raised its stake in shares of Aquestive Therapeutics by 7.2% during the fourth quarter. Bracebridge Capital LLC now owns 459,216 shares of the company's stock valued at $1,635,000 after purchasing an additional 30,645 shares during the period. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Up 2.4%

Shares of AQST stock traded up $0.06 during trading hours on Friday, reaching $2.35. 575,835 shares of the stock traded hands, compared to its average volume of 1,512,468. The firm has a market capitalization of $233.02 million, a PE ratio of -5.23 and a beta of 2.02. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $5.80. The business has a fifty day moving average price of $2.72 and a 200 day moving average price of $3.29.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to analysts' expectations of $12.23 million. Research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AQST shares. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research note on Friday, March 7th. Alliance Global Partners reaffirmed a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Lake Street Capital reduced their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Friday, March 7th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $10.67.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.